Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT: A Multicenter, Randomized Controlled Clinical Study on Efficacy and Safety

NCT04789434 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04789434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04789434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT: A Multicenter, Randomized Controlled Clinical Study on Efficacy and Safety
Lead sponsor
Ruijin Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
July 9, 2021
Completion date
July 1, 2024
Enrollment
94 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, lymphoma, large b-cell, diffuse, transplantation